![]() |
Name |
4-(5,7-dimethoxy-4-oxo-4H-chromen-2-yl)butanoic acid methyl ester
|
Molecular Formula | C16H18O6 | |
IUPAC Name* |
methyl4-(5,7-dimethoxy-4-oxochromen-2-yl)butanoate
|
|
SMILES |
COC(=O)CCCc1cc(=O)c2c(OC)cc(OC)cc2o1
|
|
InChI |
InChI=1S/C16H18O6/c1-19-11-8-13(20-2)16-12(17)7-10(22-14(16)9-11)5-4-6-15(18)21-3/h7-9H,4-6H2,1-3H3
|
|
InChIKey |
MEUIWSAUSPWBGY-UHFFFAOYSA-N
|
|
Synonyms |
NA
|
|
CAS | NA | |
PubChem CID | NA | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Molecular Weight: | 306.31 | ALogp: | 2.3 |
HBD: | 0 | HBA: | 6 |
Rotatable Bonds: | 6 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 75.0 | Aromatic Rings: | 2 |
Heavy Atoms: | 22 | QED Weighted: | 0.764 |
Caco-2 Permeability: | -4.681 | MDCK Permeability: | 0.00004520 |
Pgp-inhibitor: | 0.951 | Pgp-substrate: | 0.002 |
Human Intestinal Absorption (HIA): | 0.006 | 20% Bioavailability (F20%): | 0.008 |
30% Bioavailability (F30%): | 0.884 |
Blood-Brain-Barrier Penetration (BBB): | 0.924 | Plasma Protein Binding (PPB): | 77.24% |
Volume Distribution (VD): | 0.827 | Fu: | 20.62% |
CYP1A2-inhibitor: | 0.977 | CYP1A2-substrate: | 0.955 |
CYP2C19-inhibitor: | 0.922 | CYP2C19-substrate: | 0.839 |
CYP2C9-inhibitor: | 0.727 | CYP2C9-substrate: | 0.91 |
CYP2D6-inhibitor: | 0.158 | CYP2D6-substrate: | 0.912 |
CYP3A4-inhibitor: | 0.622 | CYP3A4-substrate: | 0.436 |
Clearance (CL): | 6.419 | Half-life (T1/2): | 0.803 |
hERG Blockers: | 0.022 | Human Hepatotoxicity (H-HT): | 0.433 |
Drug-inuced Liver Injury (DILI): | 0.628 | AMES Toxicity: | 0.371 |
Rat Oral Acute Toxicity: | 0.053 | Maximum Recommended Daily Dose: | 0.581 |
Skin Sensitization: | 0.348 | Carcinogencity: | 0.032 |
Eye Corrosion: | 0.009 | Eye Irritation: | 0.184 |
Respiratory Toxicity: | 0.082 |